Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia MG, Cupelli L, Bongarzoni V, Andriani A, Gumenyuk S, Tafuri A, Siniscalchi A, Piciocchi A, De Fabritiis P, De Rosa L, Caravita di Toritto T, Annibali O, Cantonetti M, Petrucci MT.
Fazio F, et al. Among authors: tomarchio v.
EJHaem. 2022 Jan 15;3(1):121-128. doi: 10.1002/jha2.359. eCollection 2022 Feb.
EJHaem. 2022.
PMID: 35846211
Free PMC article.